Palasis, K.A.Lokman, N.A.Quirk, B.C.Adwal, A.Scolaro, L.Huang, W.Ricciardelli, C.Oehler, M.K.McLaughlin, R.A.Abell, A.D.2021-11-052021-11-052021International Journal of Molecular Sciences, 2021; 22(19):10844-1-10844-101422-00671422-0067https://hdl.handle.net/2440/132949Local activation of an anti-cancer drug when and where needed can improve selectivity and reduce undesirable side effects. Photoswitchable drugs can be selectively switched between active and inactive states by illumination with light; however, the clinical development of these drugs has been restricted by the difficulty in delivering light deep into tissue where needed. Optical fibres have great potential for light delivery in vivo, but their use in facilitating photoswitching in anti-cancer compounds has not yet been explored. In this paper, a photoswitchable chemotherapeutic is switched using an optical fibre, and the cytotoxicity of each state is measured against HCT-116 colorectal cancer cells. The performance of optical-fibre-enabled photoswitching is characterised through its dose response. The UV–Vis spectra confirm light delivered by an optical fibre effectively enables photoswitching. The activated drug is shown to be twice as effective as the inactive drug in causing cancer cell death, characterised using an MTT assay and fluorescent microscopy. This is the first study in which a photoswitchable anti-cancer compound is switched using an optical fibre and demonstrates the feasibility of using optical fibres to activate photoswitchable drugs for potential future clinical applications.en© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Biophotonics; colorectal cancer; optical fibres; photopharmacology; photoswitchesAntineoplastic AgentsCell SurvivalColorectal NeoplasmsDimethyl SulfoxideHumansOptical FibersTumor Cells, CulturedOptical fibre-enabled photoswitching for localised activation of an anti-cancer therapeutic drugJournal article10.3390/ijms2219108442021-11-05589736Palasis, K.A. [0000-0003-1769-4240]Lokman, N.A. [0000-0002-2071-5308]Adwal, A. [0000-0001-9441-5407]Huang, W. [0000-0001-9400-3840]Ricciardelli, C. [0000-0001-7415-1854]Oehler, M.K. [0000-0002-2651-5913]McLaughlin, R.A. [0000-0001-6947-5061]Abell, A.D. [0000-0002-0604-2629]